 Interleukin-12
"Interleukin-12" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A heterodimeric cytokine that plays a role in innate and adaptive immune responses. Interleukin-12 is a 70 kDa protein that is composed of covalently linked 40 kDa and 35 kDa subunits. It is produced by DENDRITIC CELLS; MACROPHAGES and a variety of other immune cells and plays a role in the stimulation of INTERFERON-GAMMA production by T-LYMPHOCYTES and NATURAL KILLER CELLS.
| Descriptor ID |
D018664
|
| MeSH Number(s) |
D12.644.276.374.465.512 D12.776.467.374.465.512 D23.529.374.465.512
|
| Concept/Terms |
Interleukin-12- Interleukin-12
- Edodekin Alfa
- IL 12
- Natural Killer Cell Stimulatory Factor
- IL-12 p70
- IL12
- Interleukin 12
- Interleukin-12 p70
- Interleukin 12 p70
- p70, Interleukin-12
- Cytotoxic Lymphocyte Maturation Factor
- IL-12
|
Below are MeSH descriptors whose meaning is more general than "Interleukin-12".
Below are MeSH descriptors whose meaning is more specific than "Interleukin-12".
This graph shows the total number of publications written about "Interleukin-12" by people in this website by year, and whether "Interleukin-12" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 | | 1996 | 1 | 1 | 2 | | 1997 | 2 | 0 | 2 | | 1999 | 4 | 1 | 5 | | 2000 | 1 | 2 | 3 | | 2001 | 3 | 4 | 7 | | 2002 | 2 | 1 | 3 | | 2003 | 5 | 2 | 7 | | 2004 | 4 | 3 | 7 | | 2005 | 5 | 4 | 9 | | 2006 | 0 | 2 | 2 | | 2007 | 0 | 3 | 3 | | 2008 | 2 | 2 | 4 | | 2009 | 0 | 2 | 2 | | 2010 | 1 | 2 | 3 | | 2011 | 1 | 3 | 4 | | 2012 | 2 | 4 | 6 | | 2013 | 1 | 3 | 4 | | 2014 | 3 | 0 | 3 | | 2018 | 0 | 2 | 2 | | 2019 | 1 | 1 | 2 | | 2020 | 2 | 0 | 2 | | 2021 | 1 | 1 | 2 | | 2022 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Interleukin-12" by people in Profiles.
-
McDonald BD, Dyer EC, Rubin DT. IL-23 Monoclonal Antibodies for IBD: So Many, So Different? J Crohns Colitis. 2022 May 11; 16(Supplement_2):ii42-ii53.
-
Mansurov A, Hosseinchi P, Chang K, Lauterbach AL, Gray LT, Alpar AT, Budina E, Slezak AJ, Kang S, Cao S, Solanki A, Gomes S, Williford JM, Swartz MA, Mendoza JL, Ishihara J, Hubbell JA. Masking the immunotoxicity of interleukin-12 by fusing it with a domain of its receptor via a tumour-protease-cleavable linker. Nat Biomed Eng. 2022 Jul; 6(7):819-829.
-
Sattler L, Hanauer SB, Malter L. Immunomodulatory Agents for Treatment of Patients with Inflammatory Bowel Disease (Review safety of anti-TNF, Anti-Integrin, Anti IL-12/23, JAK Inhibition, Sphingosine 1-Phosphate Receptor Modulator, Azathioprine / 6-MP and Methotrexate). Curr Gastroenterol Rep. 2021 Dec 16; 23(12):30.
-
Catlett IM, Hu Y, Gao L, Banerjee S, Gordon K, Krueger JG. Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis. J Allergy Clin Immunol. 2022 06; 149(6):2010-2020.e8.
-
Akiyama S, Yamada A, Micic D, Sakuraba A. The risk of respiratory tract infections and interstitial lung disease with interleukin 12/23 and interleukin 23 antagonists in patients with autoimmune diseases: A systematic review and meta-analysis. J Am Acad Dermatol. 2021 Mar; 84(3):676-690.
-
Mansurov A, Ishihara J, Hosseinchi P, Potin L, Marchell TM, Ishihara A, Williford JM, Alpar AT, Raczy MM, Gray LT, Swartz MA, Hubbell JA. Collagen-binding IL-12 enhances tumour inflammation and drives the complete remission of established immunologically cold mouse tumours. Nat Biomed Eng. 2020 05; 4(5):531-543.
-
Trujillo JA, Luke JJ, Zha Y, Segal JP, Ritterhouse LL, Spranger S, Matijevich K, Gajewski TF. Secondary resistance to immunotherapy associated with ß-catenin pathway activation or PTEN loss in metastatic melanoma. J Immunother Cancer. 2019 11 08; 7(1):295.
-
Chiocca EA, Yu JS, Lukas RV, Solomon IH, Ligon KL, Nakashima H, Triggs DA, Reardon DA, Wen P, Stopa BM, Naik A, Rudnick J, Hu JL, Kumthekar P, Yamini B, Buck JY, Demars N, Barrett JA, Gelb AB, Zhou J, Lebel F, Cooper LJN. Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial. Sci Transl Med. 2019 08 14; 11(505).
-
Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y, Papp KA, Sofen H, Puig L, Foley P, Ohtsuki M, Flack M, Geng Z, Gu Y, Valdes JM, Thompson EHZ, Bachelez H. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018 08 25; 392(10148):650-661.
-
Stein MM, Hrusch CL, Sperling AI, Ober C. Effects of an Fc?RIIA polymorphism on leukocyte gene expression and cytokine responses to anti-CD3 and anti-CD28 antibodies. Genes Immun. 2019 07; 20(6):462-472.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|